Palisade Bio, Inc.
NASDAQ: PALI0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- J. D. Finley
- Employees
- 8
- Headquarters
- Carlsbad, United States
- IPO year
- 2007
- Market cap
- $333.3M
- Website
- https://www.palisadebio.com
Loading PALI…
Loading profile data…Frequently asked questions about PALI
What does Palisade Bio, Inc. (PALI) do?
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit di...
Where does PALI trade?
Palisade Bio, Inc. (PALI) trades on the NASDAQ Capital Market.
What sector is PALI in?
Palisade Bio, Inc. (PALI) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Palisade Bio, Inc.?
J. D. Finley is the chief executive officer of Palisade Bio, Inc. (PALI).
Where is Palisade Bio, Inc. headquartered?
Palisade Bio, Inc. is headquartered in United States.
Does PALI pay a dividend?
Palisade Bio, Inc. (PALI) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PALI go public?
Palisade Bio, Inc. (PALI) completed its initial public offering in 2007.